Maged Shenouda's Net Worth

-$251 Thousand

Estimate Recalculated Nov 1, 2024 10:26AM EST

Who is Maged Shenouda

Maged Shenouda does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include RELMADA THERAPEUTICS, INC., AzurRx BioPharma, Inc., and Protea Biosciences Group, Inc..

SEC CIK

Maged Shenouda's CIK is 0001658369

Past Insider Trading and Trends

2021 was Maged Shenouda's most active year for acquiring shares with 11 total transactions. Maged Shenouda's most active month to acquire stocks was the month of November. 2021 was Maged Shenouda's most active year for disposing of shares, totalling 25 transactions. Maged Shenouda's most active month to dispose stocks was the month of January. 2019 saw Maged Shenouda paying a total of $6,338,894.00 for 620,978 shares, this is the most they've acquired in one year. In 2021 Maged Shenouda cashed out on 72,000 shares for a total of $1,257,011.72, their largest year based on trade value.

Loading...

Attention insiders:Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

RELMADA THERAPEUTICS, INC.

Chief Financial Officer
Updated Sep 11, 2024
Form 4
153.09%
53.43K
$2.80
$149.70K
Sep 11, 2024
88.34K
Purchase
Sep 09 - Sep 11
Form 4
May 29, 2024
82.09K
Acq/Dis
May 24
Form 4
1,466.56%
32.67K
$3.85
$125.72K
Jan 31, 2024
34.90K
Purchase
Jan 29 - Jan 31
Form 4
82.09K
Dec 19, 2023
82.09K
Grant
Dec 15
Form 4
162.96%
317.64K
May 30, 2023
512.56K
Grant
May 25
Form 4
-100.00%
-200.00K
Dec 20, 2022
Disposition
Dec 16
Form 4
194.92K
Dec 20, 2022
194.92K
Grant
Dec 16
Form 4
217.66%
495.21K
May 26, 2022
722.73K
Grant
May 25
Form 4
227.52K
Dec 21, 2021
227.52K
Grant
Dec 17
Form 4
-12.11%
-10.00K
$19.35
-$322.11K
Mar 10, 2021
72.58K
Sale
ScheduledMar 08 - Mar 10
Form 4
-3.51%
-3.00K
$18.71
-$92.81K
Feb 26, 2021
82.48K
Sale
ScheduledFeb 24
Form 4
-1.64%
-1.43K
$19.32
-$45.92K
Feb 16, 2021
85.48K
Sale
ScheduledFeb 11
Form 4
-11.57%
-11.37K
$19.21
-$363.06K
Feb 10, 2021
86.91K
Sale
ScheduledFeb 08 - Feb 10
Form 4
-3.15%
-3.20K
$19.14
-$101.77K
Feb 04, 2021
98.28K
Sale
ScheduledFeb 02 - Feb 03
Form 4
-2.87%
-3.00K
$17.59
-$86.06K
Jan 29, 2021
101.48K
Sale
ScheduledJan 27
Form 4/A
179.53%
4.00K
$3.24
$12.96K
Jan 27, 2021
6.23K
Options
Jan 22
Form 4
-3.69%
-4.00K
$179.70
$1.15M
Jan 26, 2021
104.48K
Sale
ScheduledJan 22 - Jan 26
Form 4
255.00K
Jan 11, 2021
255.00K
Grant
Jan 07
Form 4
120.00K
$43.47
$5.22M
Dec 23, 2019
120.00K
Grant
Dec 19
Form 4
78.24%
978.00
$23.00
$22.49K
Oct 21, 2019
2.23K
Purchase
Oct 21
Form 4
500.00K
$2.20
$1.10M
Jul 30, 2019
500.00K
Grant
Jul 29
Form 4
450.00K
$1.15
$517.50K
Dec 20, 2018
450.00K
Grant
Dec 20
Form 4
425.00K
$0.81
$344.25K
Oct 23, 2017
425.00K
Grant
Oct 20
Form 4
150.00%
3.00K
$2.99
$8.96K
Dec 17, 2015
5.00K
Purchase
Dec 15
Form 4
2.00K
$2.89
$5.78K
Dec 16, 2015
2.00K
Purchase
Dec 14
Form 3
Nov 16, 2015
Showing 26 results

AzurRx BioPharma, Inc.

CHIEF FINANCIAL OFFICER
Updated Jan 02, 2019
Form 4
47.06%
20.00K
$1.31
$26.21K
Jan 02, 2019
62.50K
Purchase
Dec 28
Form 4
100.00K
Jul 16, 2018
100.00K
Grant
Jul 12
Form 4
112.50%
22.50K
Oct 23, 2017
42.50K
Grant
Oct 19
Form 4
100.00K
Sep 27, 2017
100.00K
Grant
Sep 25
Form 4
30.00K
Feb 07, 2017
30.00K
Grant
Feb 03
Form 3
Oct 11, 2016
20.00K
Showing 6 results

Protea Biosciences Group, Inc.

Investor
Updated Jan 07, 2016
Form 3
Jan 07, 2016
Showing 1 results